Investor Alert

New York Markets Open in:

Dec. 3, 2020, 10:48 a.m. EST

Pensievision earns a rare perfect score from the National Institute of Health (NIH) on its grant application

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Dec 03, 2020 (IssueWire via COMTEX) -- San Diego, Dec 3, 2020 ( ) - Pensievision , the company that develops AI-based, 3D medical imaging technologies, earned a rare perfect score from the National Institute of Health (NIH) on its grant application for developing a novel, low-cost, handheld, 3D imaging system for improved screening of cervical neoplasia, to help prevent cervical cancer. The grant funds, to be awarded by the National Cancer Institute (NCI), will be used for a clinical study, in collaboration with the University of California, San Diego (UCSD).

The proposal submission led by Pensievision's CTO, Dr. Joe Carson, received a perfect impact score of 10, ranking in the top one percentile of all grants submitted to the NIH.

The NIH review board indicated that "the proposal was perceived as exciting, highly innovative, extremely significant, with an exceptional investigative team, and outstanding environment".

"Even though we knew that we submitted a strong grant proposal, we were surprised by the extremely rare score," says Tal Almog, Pensievision's Co-founder. "We are honored and excited about the opportunity to accelerate the development of screening and diagnostic technologies that could help save lives"

Earlier this year, Pensievision completed the development of CervImage, the world's first portable colposcope capable of producing high-resolution 3D images to assist in early-stage detection and analysis of pre-cancer cervical lesions. The team decided to focus on cervical cancer (the third most common cancer worldwide and the leading cause of cancer death in women in developing economies, totaling 300,000 deaths per year) where screening efforts in low resource communities have only achieved limited success due to lack of laboratory infrastructure, shortage of trained personnel, and high costs, leading to high mortality rates. CervImage could improve existing screening methods by offering a point of care screening & diagnostics solution to enable single-visit screen-and-treat without the need for return visits or lab results.

Unique Team and Advisory Board

Pensievision was founded in San Diego by a unique team of four interdisciplinary professionals, Dr. Joe Carson, a professor of Astrophysics, Dr. YT Liu, a medical doctor, Tal Almog, a technology entrepreneur/executive, and Ben Carson, a business attorney. They are assisted by a seasoned advisory board, including Dr. Dennis Carson, a renowned cancer researcher and the former Director of the UCSD Moores Cancer Center, and Raymond McDaniel, CEO and President of Moody's Corporation, a $50B financial services company.

Novel Imaging Technology

The company develops medical-grade 3D imaging technologies using Dr. Carson's nontraditional approach of borrowing imaging techniques used in astronomy, such as for NASA's space telescopes. He used his own experience in extraterrestrial imaging, including his direct-imaging discovery of a 'super-Jupiter', and his discovery of the coldest imaged companion of a sun-like star (which was recognized as 'TIME magazine top 10 science discoveries of 2009').

Product Roadmap

Pensievision is working to further miniaturize its devices and is now developing a fiber-optic based endoscope to achieve precise 3D imaging of pre-cancerous lesions inside the body, including within the cervical canal, the ovaries, and the esophagus.

Pensievision's 3D imaging software could further be adapted to additional applications in consumer electronics, smartphones, and digital health. The company is currently working with market-leading strategic partners to license its technology.

Media Contact

Pensievision Inc.


Source :Pensievision Inc.

This article was originally published by IssueWire. Read the original article here.


Is there a problem with this press release? Contact the source provider Comtex at You can also contact MarketWatch Customer Service via our Customer Center.

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.